Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2092 in ABSSSI
NCT03964493Phase 2Completed
- Sponsor
- TenNor Therapeutics
- Start
- Apr 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaquizinone in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by TenNor Therapeutics. Primary endpoint: Early Clinical Response at the Early Assessment (EA) Visit. Started Apr 2019; status: completed.
02
Drugs
rifaquizinone
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT03964493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964493.